Helicobacter pylori disease is a spiral-shaped, microaerobic bacterium that requires very demanding growth conditions. It was first successfully isolated by Barry Marshall in 1983 from gastric mucosal biopsies of patients with chronic active gastritis and is the only microbial species known to be able to survive in the human stomach. He was also awarded the Nobel Prize in Medicine for this. So, H. pylori is bacterial in nature, eukaryotic, and it is able to tolerate strong acids. H. pylori can cause gastritis, peptic ulcers, lymphoproliferative gastric lymphoma, etc. Its poor prognosis is gastric cancer. And gastric cancer is one of the most common malignant tumors worldwide, ranking second in the causes of cancer death. In China, about 160,000 people die from gastric cancer every year. H. pylori bacteria are parasitic in the gastric mucosal tissues, and 67% to 80% of gastric ulcers and 95% of duodenal ulcers are caused by H. pylori. Common symptoms in patients with chronic gastritis and peptic ulcers are: fullness, discomfort or pain in the upper abdomen after eating, often accompanied by other adverse symptoms such as belching, bloating, acid reflux and loss of appetite. Therefore, early detection of H. pylori infection and timely and effective use of antimicrobial agents to kill H. pylori are of great significance in the prevention and control of gastric cancer. It is not difficult to completely eliminate H. pylori, and 90% of bacterial infections can often be eliminated after 1 to 2 weeks of treatment. However, it is also susceptible to re-infection.